EPOR erythropoietin receptor
ENSG00000187266 · protein coding · Open Targets profile
Receptor for erythropoietin, which mediates erythropoietin- induced erythroblast proliferation and differentiation (PubMed:10388848, PubMed:2163695, PubMed:2163696, PubMed:8662939, PubMed:9774108). Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade (By similarity). In some cell types, can also activate STAT1 and STAT3 (PubMed:11756159). May also activate the LYN tyrosine kinase (By similarity). {ECO:0000250|UniProtKB:P14753, ECO:0000269|PubMed:10388848, ECO:0000269|PubMed:11756159, ECO:0000269|PubMed:2163695, ECO:0000269|PubMed:2163696, ECO:0000269|PubMed:8662939, ECO:0000269|PubMed:9774108}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Antibody
- UniProt loc high conf, GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM, Human Protein Atlas loc
- PROTAC
- UniProt Ubiquitination, Small Molecule Binder
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.5828099846839905 (upper bound 0.8468800187110901). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 140 registry trials, updated in the last three years, of the most advanced drugs against EPOR (epoetin theta, epoetin zeta, efepoetin alfa, epoetin beta, epoetin alfa, methoxy polyethylene glycol-epoetin beta, peginesatide, cibinetide), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- General ManagerTanabe Pharma Corporation · 2 of 2 trials Phase 2+
- Satish KumarAzidus Principal Investigator · 1 of 2 trials Phase 2+
- Alain CariouAssistance Publique - Hôpitaux de Paris · 1 of 1 trials Phase 2+
- Alistair NicholUniversity College Dublin · 1 of 1 trials Phase 2+
- Amit K VermaECOG-ACRIN Cancer Research Group · 1 of 1 trials Phase 2+
- Annabel BlasiFundació de Recerca Clínic Barcelona - Institut D'Investigacions Biomèdiques Agustí Pí i Sunyer · 1 of 1 trials Phase 2+
- Associate Professor Craig FrenchWestern Health; ANZIC Research Centre · 1 of 1 trials Phase 2+
- Bon-Nyeo KooDepartment of Anesthesiology and Pain medicine, Severance Hospital, Seoul, South Korea · 1 of 1 trials Phase 2+
- Bristol-Myers SquibbBristol-Myers Squibb · 1 of 1 trials Phase 2+
- David A SallmanMoffitt Cancer Center · 1 of 1 trials Phase 2+
- Diego AmbrogettiInstituto de Investigaciones médicas Alfredo Lanari · 1 of 1 trials Phase 2+
- Diethard MonbaliuAbdominal transplant surgery - transplant coordination, Abdominal transplant surgery lab (microbiology & immunology Dpt) · 1 of 1 trials Phase 2+
- Franck MartinezHôpital Necker-Enfants Malades, Paris · 1 of 1 trials Phase 2+
- Gabriel ChoukrounCHU Amiens · 1 of 1 trials Phase 2+
- Geoffrey BlockUS Renal Care · 1 of 1 trials Phase 2+
Registry trials of epoetin theta, epoetin zeta, efepoetin alfa, epoetin beta, epoetin alfa, methoxy polyethylene glycol-epoetin beta, peginesatide, cibinetide updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 106 of 126 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 14 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
137 trials of drugs against EPOR were stopped early; 26 give no reason
Terminated, withdrawn and suspended interventional trials of epoetin theta, epoetin zeta, efepoetin alfa, epoetin beta, epoetin alfa, methoxy polyethylene glycol-epoetin beta, peginesatide, cibinetide, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 137.
- terminated · 2026-08-04 · GlaxoSmithKline · matched by the registry's drug synonymsNo reason given
- terminated · 2025-12-15 · VA Office of Research and Development · matched by the registry's drug synonyms“The trial was stopped because of inability to reach target sample size.”
- terminated · 2024-12-09 · Hospital Son Espases · Epoetin beta“Difficult inclusion of patients diagnosed with renal anemia in chronic hemodialysis patients without hyperparathyroidism.”
- terminated · 2024-10-04 · Belfast Health and Social Care Trust · matched by the registry's drug synonyms“Expiry of study drug - no replacement available.”
- terminated · 2024-08-01 · Kyntra Bio · matched by the registry's drug synonyms“Study did not meet its primary efficacy endpoint.”
- terminated · 2024-06-26 · Institut du Cancer de Montpellier - Val d'Aurelle · epoetin beta“After two years of trial initiation, only 27 out of 300 patients were included. During this period, the international recommendations for the use of COOL were modified.”
- terminated · 2024-04-02 · Ontario Clinical Oncology Group (OCOG) · Epoetin Alfa“Recommendation of DSMB for safety issue, increased mortality with study drug.”
- terminated · 2024-03-27 · GlaxoSmithKline · Darbepoetin alfa“The study is terminated due to feasibility in recruitment.”
- terminated · 2023-12-29 · Children's Hospital of Fudan University · matched by the registry's drug synonyms“The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.”
- terminated · 2023-01-26 · Nanjing First Hospital, Nanjing Medical University · matched by the registry's drug synonyms“lack of funds”
- withdrawn · 2023-01-26 · Karyopharm Therapeutics Inc · matched by the registry's drug synonyms“Trial never opened.”
- terminated · 2022-11-30 · Amgen · Darbepoetin alfaNo reason given
- terminated · 2022-11-29 · Amgen · Darbepoetin Alfa“FDA and EMA agreed that the information that had been submitted to date was acceptable to meet the requirements of the post-marketing commitment.”
- terminated · 2022-03-04 · University Hospital, Brest · matched by the registry's drug synonyms“inclusion difficulties”
- terminated · 2021-12-28 · Saint-Joseph University · matched by the registry's drug synonyms“For very slow recruitment”
- terminated · 2021-12-02 · University of California, San Diego · Epoetin Alfa and Iron“COVID”
- withdrawn · 2021-09-29 · Seoul National University Hospital · matched by the registry's drug synonymsNo reason given
- withdrawn · 2021-08-06 · University of Louisville · matched by the registry's drug synonymsNo reason given
- terminated · 2021-07-13 · Shire · matched by the registry's drug synonyms“The termination of the study is not linked to a product recall or result of any safety signal. Rather it was sponsor's commercial decision to withdraw the MA”
- terminated · 2021-06-24 · Sanofi · matched by the registry's drug synonyms“The study was terminated because of significant enrollment challenges”
- terminated · 2021-06-18 · Unity Health Toronto · Epoetin Alfa“The primary reasoning is that we were unable to demonstrate feasibility, prior to and because of the impact of COVID on our research programs.”
- terminated · 2021-06-14 · Shire · matched by the registry's drug synonyms“The termination of the study is not linked to a product recall or result of any safety signal. Rather it was sponsor's commercial decision to withdraw the MA”
- terminated · 2021-02-21 · Akebia Therapeutics · epoetin alfa“Revised study design.”
- terminated · 2020-10-23 · University of Texas Southwestern Medical Center · matched by the registry's drug synonyms“Initial patients were seen at St Paul Hospital. Enrollment changes occurred with the move to Clements Hospital. We were unable to identify an infusion room at CUH despite an exhaustive search for alternatives and forced to terminate early.”
- terminated · 2020-10-22 · Shenyang Sunshine Pharmaceutical Co., LTD. · matched by the registry's drug synonymsNo reason given
Paediatric incentives and obligations for EPOR's drugs
For epoetin theta, epoetin zeta, efepoetin alfa, epoetin beta, epoetin alfa, methoxy polyethylene glycol-epoetin beta, peginesatide, cibinetide: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · EPOR is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-000172-PIP01-07-M03 (Methoxy polyethylene glycol-epoetin beta, Treatment of symptomatic anaemia associated with chronic kidney disease): RPM: decision refers to a refusal on the application for modification of an agreed PIP, 31 Oct 2017; compliance positive 20 May 2022; EMEA-000646-PIP01-09-M01 (peginesatide, Treatment of symptomatic anaemia associated with chronic kidney disease): PM: decision on the application for modification of an agreed PIP, 24 Oct 2012; EMEA-000217-PIP01-08 (epoetin theta, Treatment of anaemia): W: decision granting a waiver in all age groups for all conditions or indications, 20 Jul 2008; EMEA-000219-PIP01-08 (epoetin theta, Treatment of anaemia): W: decision granting a waiver in all age groups for all conditions or indications, 20 Jul 2008; +1 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/16/1721 positive 29 Aug 2016: Prevention of graft loss in pancreatic islet transplantation; EU/3/13/1191 positive 7 Oct 2013: Treatment of sarcoidosisRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Silapo: authorised since 18 Dec 2007; Retacrit: authorised since 18 Dec 2007; Mircera: authorised since 20 Jul 2007; NeoRecormon: authorised since 16 Jul 1997; +8 moreRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of epoetin theta, epoetin zeta, efepoetin alfa, epoetin beta, epoetin alfa, methoxy polyethylene glycol-epoetin beta, peginesatide, cibinetideRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 108 interventional studies of epoetin theta, epoetin zeta, efepoetin alfa, epoetin beta, epoetin alfa, methoxy polyethylene glycol-epoetin beta, peginesatide, cibinetide include patients under 18; 6 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 11 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.